Apo-Propafenone

Apo-Propafenone is indicated for the prophylaxis and treatment of ventricular arrhythmias.

Apo-Propafenone is also indicated for the prophylaxis and treatment of paroxysmal supraventricular tachyarrhythmias which include paroxysmal atrial flutter/fibrillation and paroxysmal re-entrant tachycardia's involving the AV node or accessory bypass tracts, when standard therapy has failed or is contraindicated.

It is recommended that Apo-Propafenone therapy should be initiated under hospital conditions, by a physician experienced in the treatment of arrhythmias. The individual maintenance dose should be determined under cardiological surveillance including ECG monitoring and blood pressure control. If the QRS interval is prolonged by more than 160msec or the PQ interval is prolonged by more than 20%, the dose should be reduced or discontinued until the ECG returns to normal limits.

Adults

Initially, 150 mg three times daily increasing at a minimum of three-day intervals to 300 mg twice daily and if necessary, to a maximum of 300 mg three times daily.

The tablets should be swallowed whole and taken with a drink after food. A reduction in the total daily dose is recommended for patients below 70 kg bodyweight.

Elderly

No overall differences in safety or effectiveness were observed in this patient population, but greater sensitivity of some older individuals cannot be ruled out, therefore, these patients should be carefully monitored. Treatment should be initiated gradually and with particular caution in small incremental doses. The same applies to maintenance therapy. Any dose increases that may be required should not be undertaken until after five to eight days of therapy.

Children

A suitable dosage form of Apo-Propafenone hydrochloride tablets for children is not available.

Hepatic/Renal Impairment

In patients whose liver and/or kidney function is impaired, there may be drug accumulation after standard therapeutic doses. Nonetheless, patients with these conditions can still be titrated on Apo-Propafenone hydrochloride under ECG and plasma level monitoring.

Minor prolongation of the PR interval and intra-ventricular conduction defects (QRS duration of less than 20%) are to be expected during treatment with Apo-Propafenone and do not warrant dose reduction or drug withdrawal.

Due to the potential for increased plasma concentrations, co-administration of ritonavir and Apo-Propafenone hydrochloride is contraindicated.

Electrolyte disturbances should first be treated before treatment with Apo-Propafenone.

The weak negative inotropic effect of Apo-Propafenone may assume importance in patients predisposed to cardiac failure. In common with other anti-arrhythmic drugs, Apo-Propafenone has been shown to alter sensitivity and pacing threshold.

In patients with pacemakers, appropriate adjustments may be required. There is potential for conversion of paroxysmal atrial fibrillation to atrial flutter with accompanying 2:1 conduction block or 1:1 conduction.

Because of the beta-blocking effect, care should be exercised in the treatment of patients with obstructive airways disease or asthma.

As with some other class IC anti-arrhythmic agents, patients with significant structural heart disease may be predisposed to serious adverse effects. Therefore Apo-Propafenone is contraindicated in these patients.

There is a risk of pro-arrhythmic effects, as with other anti-arrhythmics. Worsening of the ventricular arrhythmias is possible.

A Brugada syndrome may be unmasked or Brugada like electrocardiogram (ECG) changes may be provoked after exposure to Apo-Propafenone in previously asymptomatic carriers of the syndrome. After initiating therapy with Apo-Propafenone, an ECG should be performed to rule out changes suggestive of Brugada syndrome.

For the treatment of ventricular arrhythmias, the patient should be under cardiological surveillance including ECG monitoring and blood pressure control and defribillator facilities should be available.

Treatment stop should be considered with one of the following ECG-changes:

- QRS or QT-interval prolongation with more than 25%,

- PR-interval prolongation with more than 50%,

- QT-interval prolongation with more than 500 msec,

- or a increase in numbers or worsening of the arrhythmias

It is essential that each patient given Apo-Propafenone hydrochloride be evaluated electrocardiographically and clinically prior to and during therapy to determine whether the response to Apo-Propafenone hydrochloride supports continued treatment.

Blurred vision, dizziness, fatigue and postural hypotension may affect the patient's speed of reaction and impair the individual's ability to operate machinery or motor vehicles.

a. Summary of the safety profile

The most frequent and very common adverse reactions related to Apo-Propafenone therapy are dizziness, cardiac conduction disorders and palpitations.

b. Tabulated summary of adverse reactions

The following table displays adverse reactions reported in clinical trials and from post-marketing experience with Apo-Propafenone.

The reactions considered at least possibly related to Apo-Propafenone are displayed by system organ class and frequency using the following convention: very common (>1/10), common (> 1/100 to < 1/10), uncommon (>1/1,000 to < 1/100) and not known (adverse reactions from post-marketing experience; cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness when the seriousness could be assessed. The frequencies are based on clinical trial data from Apo-Propafenone SR. It is expected that the adverse reactions and frequencies for IR formulations would be similar.

¹ May be manifested by cholestasis, blood dyscrasias and rash

² Excluding vertigo

³ Including sinoatrial block, atrioventricular block and intraventricular block

⁴ Apo-Propafenone may be associated with proarrhythmic effects which manifest as an increase in heart rate (tachycardia) or ventricular fibrillation. Some of these arrhythmias can be life- threatening and may require resuscitation to prevent a potentially fatal outcome

⁵ An aggravation of preexisting cardiac insufficiency may occur

⁶ This term covers abnormal liver function tests, such as aspartate aminotransferase increased, alanine aminotransferase increased, gamma-glutamyltransferase increased and blood alkaline phosphatase increased

⁷ Decreased sperm count is reversible upon discontinuation of Apo-Propafenone

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

Symptoms of overdosing:

Myocardial symptoms: The effects of Apo-Propafenone overdose in the myocardium manifest as impulse generation and conduction disorders such as PQ prolongation, QRS widening, suppression of sinus node automaticity, AV block, ventricular tachycardia and ventricular fibrillation. Reduction of contractility (negative inotropic effect) can cause hypotension which, in severe cases, can lead to cardiovascular shock.

Non-cardiac symptoms: Headache, dizziness, blurred vision, paraesthesia, tremor, nausea, constipation and dry mouth may occur frequently. In extremely rare cases, convulsions have been reported on overdose. Death has also been reported.

In severe cases of poisoning, clonic-tonic convulsions, paraesthesia, somnolence, coma and respiratory arrest may occur.

Treatment:

In addition to general emergency measures, the patient's vital parameters should be monitored in an intensive care setting, and rectified, as appropriate.

Defibrillation as well as infusion of dopamine and isoproterenol have been effective in controlling rhythm and blood pressure. Convulsions have been alleviated with intravenous diazepam. General supportive measures such as mechanical respiratory assistance and external cardiac massage may be necessary.

Attempts to achieve elimination via haemoperfusion are of limited efficacy.

Owing to high protein binding (> 95%) and the large volume of distribution, haemodialysis is ineffective.

ATC code for Apo-Propafenone is C01B C03.

Apo-Propafenone is a class IC anti-arrhythmic agent.

It has a stabilising action on myocardial membranes, reduces the fast inward current carried by sodium ions with a reduction in depolarisation rate and prolongs the impulse conduction time in the atrium, AV node and primarily, in the His-Purkinje system.

Impulse conduction through accessory pathways, as in WPW syndrome, is either inhibited, by prolongation of the refractory period or blockade of the conduction pathway, both in anterograde but mostly retrograde direction.

At the same time, spontaneous excitability is reduced by an increase of the myocardial stimulus threshold while electrical excitability of the myocardium is decreased by an increase of the ventricular fibrillation threshold.

Anti-arrhythmic effects: Slowing of upstroke velocity of the action potential, decrease of excitability, homogenisation of conduction rates, suppression of ectopic automaticity, lowered myocardial disposition to fibrillation.

Apo-Propafenone has moderate beta-sympatholytic activity without clinical relevance. However, the possibility exists that high daily doses (900 - 1200 mg) may trigger a sympatholytic (anti-adrenergic) effect.

In the ECG, Apo-Propafenone causes a slight prolongation of P, PR and QRS intervals while the QTC interval remains unaffected as a rule.

In digitalised patients with an ejection fraction of 35-50%, contractility of the left ventricle is slightly decreased. In patients with acute transmural infarction and heart failure, the intravenous administration of Apo-Propafenone may markedly reduce the left ventricular ejection fraction but to an essentially lesser extent in patients in the acute stages of infarction without heart failure. In both cases, pulmonary arterial pressure is minimally raised. Peripheral arterial pressure does not show any significant changes. This demonstrates that Apo-Propafenone does not exert an unfavourable effect on left ventricular function which would be of clinical relevance. A clinically-relevant reduction of left ventricular function is to be expected only in patients with pre-existing poor ventricular function.

Untreated heart failure might then deteriorate possibly resulting in decompensation.

Apo-Propafenone is a racemic mixture of S- and R-Apo-Propafenone.

Absorption

Following oral administration, Apo-Propafenone is nearly completely absorbed from the gastrointestinal tract in a dose-dependent manner. Maximal plasma concentrations are reached between two to three hours following the administration of Apo-Propafenone hydrochloride.

After a single dose of one tablet, bioavailability is about 50%. With repeated doses, plasma concentration and bioavailability rise disproportionately due to saturation of the first pass metabolism (CYP2D6) in the liver. Although food increased the maximal plasma concentration and bioavailability in a single dose study, during multiple dose administration of Apo-Propafenone to healthy subjects, food did not change bioavailability significantly.

Distribution

Apo-Propafenone distributes rapidly in the body. The steady-state volume of distribution is 1.9 to 3.0 L/kg.

Therapeutic plasma levels are in the range of 150 ng/mL to 1500 ng/mL. The degree of plasma protein binding of Apo-Propafenone is concentration dependent and decreased from 97.3% at 0.25 μg/mL to 81.3% at 100 μg/mL. In the therapeutic concentration range, more than 95% of Apo-Propafenone is bound to plasma proteins.

Biotransformation and elimination

Comparing cumulative urinary excretion over 24 hours allowed for the calculation that 1.3% of intravenous (70 mg) and 0.65% of oral (600 mg) Apo-Propafenone is excreted unchanged in the urine, i.e. Apo-Propafenone is almost exclusively metabolised in the liver. The estimated Apo-Propafenone elimination half-life ranges from 2 to 10 hours for extensive metabolisers and from 10 to 32 hours for poor metabolisers. A close positive correlation between plasma level and AV conduction time was seen in the majority of both healthy volunteers and patients. Clearance of Apo-Propafenone is 0.67 to 0.81 L/h/kg.

After a plasma level of 500 ng/ml, the PR interval is statistically significantly prolonged as compared to baseline values which allows for dose titration and monitoring of the patients with the help of ECG readings. The frequency of ventricular extrasystoles decreases as plasma concentrations increase. Adequate anti-arrhythmic activity has, in single cases, been observed at plasma levels as low as <500 ng/ml.

Steady state is reached after 3 or 4 days, when bioavailability increases to about 100%. The recommended dosing regimen of Apo-Propafenone is the same regardless of the metabolic status (i.e., poor or extensive metabolizers) for all patients.

Elderly population

Apo-Propafenone exposure in elderly subjects with normal renal function was highly variable, and not significantly different from healthy young subjects. Exposure to 5-hydroxyApo-Propafenone was similar, but exposure to Apo-Propafenone glucuronides was doubled.

Renal impairment

Even in the presence of impaired renal function, reduced elimination of Apo-Propafenone is not likely, which is confirmed by case reports and single kinetic studies in patients on chronic haemodialysis. However, accumulation of glucuronide metabolites was observed. Clinical chemistry values did not differ from those of patients with uncompromised kidneys. Apo-Propafenone hydrochloride should be administered cautiously in patients with renal disease.

Liver impairment

Apo-Propafenone shows an increased oral bioavailability and half-life in patients with liver impairment. The dosage must be adjusted in patients with liver disease.

None.

Not applicable

Any unused product or waste material should be disposed of in accordance with local requirements.